Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 17/20 | 0.47 |
| ▸ | MMP13 | P45452 | 2/20 | 0.47 |
| ▸ | MMP2 | P08253 | 2/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | MMP7 | P09237 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MMP14 | P50281 | 1/20 | 0.44 |
| ▸ | MMP15 | P51511 | 1/20 | 0.44 |
| ▸ | MMP16 | P51512 | 1/20 | 0.44 |
| ▸ | ADAM33 | Q9BZ11 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5041747 | 0.87 | ADAM17 (0.49) | ADAM17MMP13MMP2MMP1MMP3 | |
| SCHEMBL5036697 | 0.85 | ADAM17 (0.48) | ADAM17MMP13MMP2MMP1MMP3 | |
| SCHEMBL5041676 | 0.83 | ADAM17 (0.54) | ADAM17MMP13MMP2MMP1MMP3 | |
| SCHEMBL5039643 | 0.82 | ADAM17 (0.53) | ADAM17MMP13MMP2MMP1MMP3 | |
| SCHEMBL5035407 | 0.80 | ADAM17 (0.48) | ADAM17MMP13MMP2MMP1MMP3 | |
| SCHEMBL5041757 | 0.77 | ADAM17 (0.45) | ADAM17MMP13MMP2MMP1MMP3 | |
| SCHEMBL5036461 | 0.73 | ADAM17 (0.53) | ADAM17MMP13MMP2 | |
| SCHEMBL7373515 | 0.70 | ADAM17 (0.60) | ADAM17MMP13MMP2MMP1MMP3 | |
| SCHEMBL5884537 | 0.69 | ADAM17 (0.69) | ADAM17MMP13MMP2MMP3MMP7 | |
| SCHEMBL5041675 | 0.69 | ADAM17 (0.53) | ADAM17MMP13MMP2MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1628974-A4 | HYDANTOIN DERIVATIVES AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME (TACE) | BRISTOL MYERS SQUIBB CO (US) | 2008-05-07 | — | — | EP | disclosed |
| EP-1628974-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME (TACE) | Bristol-Myers Squibb Company (US) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004108086-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF TUMOR NECROSIS FACTOR-α CONVERTING ENZYME (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-16 | — | — | WO | disclosed |